Evidence map›Paper›PMID 40710376›Full record

ArticleCells2025

Impact of the Use of 2-Phospho-L Ascorbic Acid in the Production of Engineered Stromal Tissue for Regenerative Medicine.

David Brownell, Laurence Carignan, Reza Alavi, Christophe Caneparo, Maxime Labroy, Todd Galbraith, Stéphane Chabaud, François Berthod, Laure Gibot, François Bordeleau and 1 more

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

David BrownellRegenerative Medicine Division, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0009-0002-8034-5385
Laurence CarignanCentre de Recherche en Organogénèse Expérimentale de L'Université Laval/LOEX, Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0009-0005-4751-0475
Reza AlaviCentre de Recherche en Organogénèse Expérimentale de L'Université Laval/LOEX, Université Laval, Québec, QC G1J 5B3, Canada.
Christophe CaneparoRegenerative Medicine Division, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0000-0003-0811-0688
Maxime LabroyCentre de Recherche en Organogénèse Expérimentale de L'Université Laval/LOEX, Université Laval, Québec, QC G1J 5B3, Canada.
Todd GalbraithRegenerative Medicine Division, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
Stéphane ChabaudRegenerative Medicine Division, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0000-0002-0389-667X
François BerthodRegenerative Medicine Division, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0000-0003-3580-0297
Laure GibotUniversité de Toulouse, CNRS UMR 5623, Laboratoire Softmat, 31062 Toulouse, France.ORCID 0000-0001-7255-4123
François BordeleauCentre de Recherche en Organogénèse Expérimentale de L'Université Laval/LOEX, Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0000-0002-5114-1757
Stéphane BolducRegenerative Medicine Division, Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0000-0001-6680-5563

Funding

CIHR 178186CIHR 258229Fonds de recherche du Québec - Nature et technologies-Samuel-de-Champlain 302260Fonds de recherche du Québec - Santé 329444Natural Sciences and Engineering Research Council of Canada RGPIN-2018-06214
6 · The paper itself

Abstract

Tissue engineering enables autologous reconstruction of human tissues, addressing limitations in tissue availability and immune compatibility. Several tissue engineering techniques, such as self-assembly, rely on or benefit from extracellular matrix (ECM) secretion by fibroblasts to produce biomimetic scaffolds. Models have been developed for use in humans, such as skin and corneas. Ascorbic acid (vitamin C, AA) is essential for collagen biosynthesis. However, AA is chemically unstable in culture, with a half-life of 24 h, requiring freshly prepared AA with each change of medium. This study aims to demonstrate the functional equivalence of 2-phospho-L-ascorbate (2PAA), a stable form of AA, for tissue reconstruction. Dermal, vaginal, and bladder stroma were reconstructed by self-assembly using tissue-specific protocols. The tissues were cultured in a medium supplemented with either freshly prepared or frozen AA, or with 2PAA. Biochemical analyses were performed on the tissues to evaluate cell density and tissue composition, including collagen secretion and deposition. Histology and quantitative polarized light microscopy were used to evaluate tissue architecture, and mechanical evaluation was performed both by tensiometry and atomic force microscopy (AFM) to evaluate its macroscopic and cell-scale mechanical properties. The tissues produced by the three ascorbate conditions had similar collagen deposition, architecture, and mechanical properties in each organ-specific stroma. Mechanical characterization revealed tissue-specific differences, with tensile modulus values ranging from 1-5 MPa and AFM-derived apparent stiffness in the 1-2 kPa range, reflecting the nonlinear and scale-dependent behavior of the engineered stroma. The results demonstrate the possibility of substituting AA with 2PAA for tissue engineering. This protocol could significantly reduce the costs associated with tissue production by reducing preparation time and use of materials. This is a crucial factor for any scale-up activity.

Indexed as

Ascorbic AcidRegenerative MedicineStromal CellsTissue EngineeringCollagenExtracellular MatrixFemaleFibroblastsHumansTissue Scaffoldsascorbate-2-phosphateAscorbic AcidCollagen2-phospo-L-ascorbateextracellular matrixhuman primary fibroblastssodium L-ascorbatetissue engineering

Identifiers

PMID40710376
PMCPMC12293852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.